• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

World AIDS Day 2015: Paediatric HIV projects update from the team

Home > News

World AIDS Day 2015: Paediatric HIV projects update from the team

Paediatric HIV Advocacy Toolkit
Paediatric HIV Advocacy Toolkit
1 Dec 2015
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

At the close of 2015, we would like to take this opportunity to update you on the status of DNDi’s paediatric HIV 4-in-1 formulation development programme.

DNDi’s research and development (R&D) programme aims to develop two improved child-friendly lopinavir/ritonavir (LPV/r)-based fixed dose combinations (4-in-1s) and develop a strategy to counteract the negative drug-drug interaction between lopinavir/ritonavir (LPV/r) and rifampicin during TB/HIV co-infection in children.

In 2011, we began to explore various formulation options, including prodrugs of LPV and RTV, nanosuspension and nanoparticles of LPV and RTV as well as LPV/r pellets developed by Cipla Ltd in collaboration with partners (MRC and clinical trial sites in Uganda), tested in the CHAPAS-2 study. The CHAPAS 2 results demonstrated good bioavailability of the LPV/r pellets in comparison with LPV/r syrup in children less than one year old, as well as in comparison with AbbVie’s heat stable LPV/r tablets in children aged four and above. The acceptability of the LPV/r pellets was good in the younger cohort but taste remained an issue with the older cohort. Based on these results, DNDi decided to support an additional comparative bioavailability and acceptability study of the pellets versus the liquid formulation in children aged one to four years old. Nonetheless, the LPV/r pellets still represent an improvement over the liquid formulation because they are heat stable, do not contain alcohol and other toxic excipient, are logistically easier to manage, dose, and administer.

The dossier of LPV/r pellets was submitted by Cipla Ltd. to the US Food and Drug Administration (US FDA) in 2013 and received US FDA tentative approval in May 2015.

Due to the urgency to use a better adapted formulation of LPV/r for the treatment of infants and young children in resource limited settings, DNDi decided to introduce Cipla’s LPV/r pellets in the field through implementation studies in various countries. The focus is on assessing acceptability of the formulation (ease of administration, instructions for use across different age groups, acceptability by children, caregivers, and healthcare workers) and the feasibility of using it in real life settings. These studies will provide early access to the pellets and knowledge gained will be important for treatment scale up at the country level, adoption by programs and faster product registration. The trial has started in Kenya, and we plan to extend it as soon as possible to several additional countries. The aim is for the study to support and help to accelerate the registration process, including through the WHO Prequalification Programme. It equally aims to support change of policy/treatment guidelines at country level.

In the meantime, DNDi continues its collaboration with Cipla Ltd. on improving the taste-masking of solid formulations of LPV/r and to combine LPV/r with two NRTI pairs (AZT/3TC or 3TC/ABC) in a single dosage form (fixed dose combination). Cipla Ltd. is responsible for the pharmaceutical development work (formulation screening, process development and analytics), product registration and conduct of Phase I, healthy human volunteer bioavailability studies, while DNDi manages clinical development including the implementation studies referred to above, using the LPV/r pellets developed by Cipla Ltd. While these studies provide early access to the pellets, they will be switched to the 4-in-1 formulations as soon as they are available.

A first Phase I study using a well taste masked LPV/r granules formulation was performed in healthy human volunteers in 2013. You may remember that this study showed a very large variability of Cmax and AUC’s as well as low bioavailability, approximately half of that of the reference LPV/r syrup.

The challenges of working with LPV and RTV are well-known. These molecules are highly insoluble, lipophilic and do not cross the gastro-intestinal barrier easily (Biopharmaceutical Class IV). The individual active ingredients interact with each other and with the transport and metabolism enzymes of the gut and the liver. They taste very bitter thus cannot be made into a dispersible tablet and require melt extrusion technology to enhance solubility.

Following these Phase I results, DNDi and Cipla Ltd. teams decided to evaluate different formulations of LPV/r focusing on bioavailability, stability and taste masking before moving forward to human studies. Various taste-masked granule formulations were tested while keeping coated LPV/r pellet formulations as backup options. A series of about 40 LPV/r formulations were tested in pre-clinical models to confirm bioavailability before proceeding to Phase I studies.

As of November 2015, six taste masked LPV/r formulations have been identified which could demonstrate good bioavailability. The quality of the taste masking needs to be confirmed for a few of the formulations. Three LPV/r formulations have already been tested in Phase I studies in comparison with the reference LPV/r syrup. The results showed high bioavailability of all three formulations compared to the LPV/r syrup.

This is where we are today, and are in the process of selecting the most promising formulation for further development. While the plan is to immediately switch out the ARVs currently being tested in the implementation studies to introduce the 4-in-1s, we may have to conduct a Phase II/III before being able to file for their registration.

We have also progressed on the super boosting strategy by which extra RTV is added to the existing LPV/r formulation to achieve a 1:1 ratio between LPV and RTV during TB treatment containing rifampicin was based on scant data and needed to be validated. DNDi worked with investigators from South Africa to design a pharmacokinetic study involving 90 children with the objective to show that under super boosting, LPV/r levels are similar to those obtained after HIV/TB co-therapy. Recruitment into the study commenced in January 2013 and an interim analysis was performed in 2015 and presented at a Paediatric HIV Workshop held in Vancouver in July 2015. While we still need to complete the analysis, interim results were very encouraging. We are currently completing the follow-up and analysis of this study, and plan to conduct a similar study using LPV/r pellets from Cipla Ltd. and ritonavir oral powder from AbbVie in South Africa.

 

Paediatric HIV

Read, watch, share

Loading...
Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

Best science for all

Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License